M ost cases of acute leukemia can be assigned a specific lineage: acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) according to the morphologic, cytochemical, and immunophenotypic characteristics of the blasts cells. A minority of patients with acute leukemia has immunophenotypic feature characteristics of >1 cell lineage. These cases are designated as biphenotypic acute leukemia (BAL) or bilineal leukemia. To distinguish between BAL and acute leukemia having aberrant expression of other lineages, BAL was defined according to a scoring system adopted by the European Group for the Immunological Classification of Leukemia (EGIL). 1, 2 This system is based on the number and degree of specificity of the lymphoid B/T and myeloid markers expressed simultaneously by the blasts. The World Health Organization (WHO) now terms BAL mixed phenotype acute leukemia (MPAL), and the new definition is more stringent than the EGIL scoring proposal. 3 Knowledge of the biology, clinical characteristics, and outcomes of patients with mixed lineage leukemia is limited in Morocco, so we analyzed 17 patients with BAL and 3 with bilineal leukemia diagnosed during a 6-year period.
PATIENTS AND METHODS

Patients
From January 2004 to December 2010, 1264 adult and pediatric patients with newly diagnosed acute leukemia were treated at the Haematology and Paediatric Oncology services of University Hospitals of Rabat and Casablanca and were referred to the National Institute of Hygiene and the pediatric Rabat unit laboratories of Rabat for immunophenotyping. Twenty (1.5%) patients were diagnosed with de novo mixed leukemia and are the subject of this study. The Rabat and Casablanca units are the only specialized public facilities for pediatric and adult leukemia patients in Morocco. A diagnosis of ALL or AML was made according to the morphologic, cytochemical, and immunophenotypic characteristics of the blast cells.
Flow Cytometric Analysis and Diagnostic Criteria
The immunophenotype was performed on bone marrow aspirates or peripheral blood samples collected in EDTA with a panel of antibodies to leukocytes-associated markers. Immunophenotypic characterization consisted of 2 consecutive steps. The first panel included CD10, CD19, CD22, CD79a, CD3 (surface and cytoplasmic), CD7, CD13, CD33, myeloperoxidase (MPO), HLADR, CD34, terminal deoxynucleotidyl transferase, and CD45. The first panel considers the most lineage specific markers and is able to identify the lineage in the majority of leukemia cases. According to the results obtained, additional markers (secondary panel) were considered, including CD1a, CD2, CD4, CD5, CD8, CD11b, CD11c, CD14, CD36, CD61, CD41a, and CD117.
Stained cells were analyzed by flow cytometry on a 3-color FACSCalibur flow cytometer (Becton Dickinson Immunocytometry Systems) by collecting 10,000 ungated list mode events. Blasts initially were gated for analysis by using CD45 versus light side scatter. Leukemic samples were considered positive for a particular antigen if Z20% of leukemic cells reacted with an antibody. The diagnosis of BAL was on the basis of the first immunophenotypic evaluation of the blast population; if cases had lymphoid and myeloid markers or both T-lineage and B-lineage markers, an extensive immunophenotyping was performed to support the diagnosis. The final diagnosis of BAL was made according to a scoring system adopted by the EGIL. 1,2 Initially, 26 cases were diagnosed as BAL and 3 cases as bilineal leukemia. The BAL cases were reanalyzed according to 2008 WHO classification of tumors of hematopoietic and lymphoid tissues 3 and were categorized as having MPAL, but 9 patients were not confirmed as having MPAL because of the weak expression of B markers: in 5 patients, classified as T-ALL in 3 and a diagnosis of AML in 2; 4 cases lacked the expression of MPO and were classified as T-ALL in 3 cases and as B-ALL in 1 case. Finally, 20 were classified as having MPAL, including 17 with BAL and 3 with bilineal leukemia.
Cytogenetics
Cytogenetic analysis was performed on the bone marrow by the direct preparation of unstimulated cells after 24 hours in culture at 371C on a culture medium RPMI 1640, 1 Â.
The R-banding method was used to prepare metaphase cells. The karyotype was performed according to the International System of Human Cytogenetic Nomenclature 2008. 4 At least 20 mitoses were examined.
Treatment
Patients were treated with national Moroccan protocols for AML or ALL (AML-MA03 http://www.smccbm. org/fichiers_pdf/conferencesjib2009/3-JIB2009_Quessar.pdf) and Marall06 (Table 1) or LALA 94. 5 Complete remission (CR) was defined as <5% blasts in the bone marrow with recovery from cytopenias.
Statistical Methods
The Kaplan-Meier method was used to estimate the probability of overall and event-free survival. Survival analysis was performed using a SYSTAT version 12. 
RESULTS
Patient Characteristics
Among the 1264 adult and pediatric patients (511 female and 753 male patients) with newly diagnosed acute leukemia, 610 had B-lineage ALL, 225 had T-lineage ALL, 409 had AML, 17 had BAL (1.3%), and 3 had bilineal leukemia (0.2%), and so a total of 20 had MPAL and were included in this study.
Of the 17 BAL patients, 16 cases were de novo and 1 was secondary BAL (case 11; whose original disease was AML). For bilineal patients, 2 cases were de novo and 1 was secondary (case 19; whose original disease was ALL). Clinical and biological features of the patients are summarized in Tables 2 and 3 . The patients ranged in age from 1 to 69 years (median, 11.5 y). There were 13 male and 7 female patients, including 12 children and 8 adults. Three of the pediatric patients had a mediastinal mass. The white blood cell count was moderate to high (mean, 63 Â10 9 /L) and circulating blasts were usually present. According to French-American-British criteria, 11 had morphology resembling AML and 9 were consistent with ALL. 
Immunophenotyping
The immunophenotype of all patients is shown in Table 2 . In BAL patients, double staining confirmed the coexpression of lymphoid and myeloid markers in a variable proportion of blasts. In addition, 3 cases had 2 distinct lymphoid B or T and myeloid populations and were classified as bilineal leukemia. The majority of cases expressed early hematopoietic markers, such as CD34 (90%) and class II HLA-DR determinants (74%). For patients with myeloid lineage disease, the most frequent positive markers were MPO, CD33, CD13, and CD117 in 88%, 76%, 70%, and 47% of cases, respectively. For B lymphoid lineage, all patients expressed CD19, CD22, and CD79a and 50% expressed CD10. All T-lineage patients were positive for cCD3 and CD7, 47% showed a weak expression of sCD3, and none of them expressed CD4. The expression of the other T-lymphoid markers was as follows: CD5 was 67%, CD1a was 21%, and CD8 was 14%.
Cytogenetic Abnormalities
Cytogenetic analysis was successfully carried out in 10 patients (Table 2) . A normal karyotype was found in 4 cases (40%), whereas clonal abnormalities were seen in 6 cases (60%). One had an abnormality in 11q23, another had a complex karyotype, and 2 were hypodiploid.
Treatment and Outcome
The initial chemotherapy regimens and clinical outcome are summarized in Table 3 . In the 4 patients who received AML therapy, 2 BAL patients achieved CR, 1 showed no response, and 1 patient with bilineal leukemia died of toxicity. In the 14 patients who received ALL therapy initially, 10 patients achieved CR (71%), 3 showed no response, and 1 died of toxicity. The other 2 patients were given palliative treatments (cases 8 and 9): 1 treated with palliative single-agent mercaptopurine showed no response and 1 achieved CR after treatment with hydroxyurea monotherapy. Neither of the patients with secondary leukemia achieved CR and both died of progressive leukemia at 0.7 and 2 months from diagnosis (cases 19 and 11).
Overall, 13 patients entered CR (65%, 13/20) after initial induction therapy. Of patients achieving CR after induction therapy, the relapse rate was higher in adults than in children: 2 of 3 adults and only 1 of 8 children relapsed. All relapsed cases died of disease. Two CR patients died of chemotherapy toxicity. Overall, 13 patients died (65%, 13/ 20): the cause of death was chemotherapy toxicity in 4 patients, relapse in 3, and resistant disease in 6 patients. At last follow-up, 7 of the 13 patients achieving CR were still alive and were in remission after treatment for ALL, among whom, 6 were below 15 years of age.
The survival of patients with de MPAL is shown in Figure 1 . The median follow-up was 11.04 months (range, 0.72 to 64.2 mo) and median survival time was 19.3 months. The probability of survival at 2 years is 52% ± 14%. Patients initially treated with ALL-directed therapy had better outcomes than those treated initially with AML-directed therapy (P = 0.003, Fig. 2 ). There was no significant difference in survival between children and adults [67% ± 16% (n = 13) vs. 25% ± 22% (n = 7), P = 0.42] or between patients with different immunophenotypes (Fig. 3) .
DISCUSSION
Mixed-lineage leukemia represents an uncommon and heterogenous disease. BAL represents an important subgroup from this category and generally accounting for <5% of acute leukemia using the EGIL scoring system. [6] [7] [8] In this study, the incidence of BAL is 1.3% and 0.2% for bilineal leukemia. This incidence is in agreement with the studies fulfilling the new criteria of the WHO classification. [9] [10] [11] We identified 17 cases of BAL and the majority are those with myeloid and T-lymphoid phenotype (11/17, 64.7%). This frequency is higher than that in previous studies [6] [7] [8] but is in agreement with the series with the WHO criteria. 10, 11 The cases coexpressing B-lymphoid and Tlymphoid markers (3/17, 17.6%) are higher than those reported in the literature. 6, [9] [10] [11] [12] The differences observed are probably due to the high frequency of T-ALL phenotype in our population. 13, 14 The expression of surface CD3 was observed in the majority of our cases (9/15, 63%).
Six of 10 cases with successful cytogenetic analysis had chromosome abnormalities, including 3 with unfavorable karyotypes. The cytogenetic studies available in BAL 6, 8, [10] [11] [12] 15, 16 and bilineal leukemia 11, 17 had shown a high incidence of clonal abnormalities and unfavorable karyotypes. 6, 15, 16 The optimal treatment for patients with mixed-phenotype leukemia is unknown, but ALL regimens are usually effective and remain our standard initial therapy. 6, [10] [11] [12] Data in response to the therapy and outcome show that our cases seemto respond to either AML or ALL induction therapy, and there was statistical difference when comparing patients according to initial therapy (P = 0.003)-ALLdirected treatment seems to be more effective.
Pediatric cases have been found to have better prognostics when compared with adults, but were inferior when compared with children having ALL. 6, 11, 12 This is consistent with our series, in which 6 of 12 children survived but only 1 of 8 adults survived. In addition, as demonstrated by previous studies 6, 11, 12 no apparent association was seen between the phenotypic characteristics of our patients and clinical outcome. In conclusion, MPAL represents 1.5% of acute leukemia in Morocco. BAL represents the most frequent subgroup from this category and has a poor prognosis in both children and adults. Initial treatment with therapy directed toward ALL, improved supportive care, and prevention of abandonment of therapy may improve outcomes for this subgroup of patients.
